Version 1
: Received: 28 October 2023 / Approved: 1 November 2023 / Online: 1 November 2023 (08:31:47 CET)
How to cite:
aventurato, I. Current Status of Nanomedicine in CNS Cancer Therapeutics in the Post-COVID-19 Era. Preprints2023, 2023110017. https://doi.org/10.20944/preprints202311.0017.v1
aventurato, I. Current Status of Nanomedicine in CNS Cancer Therapeutics in the Post-COVID-19 Era. Preprints 2023, 2023110017. https://doi.org/10.20944/preprints202311.0017.v1
aventurato, I. Current Status of Nanomedicine in CNS Cancer Therapeutics in the Post-COVID-19 Era. Preprints2023, 2023110017. https://doi.org/10.20944/preprints202311.0017.v1
APA Style
aventurato, I. (2023). <strong></strong>Current Status of Nanomedicine in CNS Cancer Therapeutics in the Post-COVID-19 Era. Preprints. https://doi.org/10.20944/preprints202311.0017.v1
Chicago/Turabian Style
aventurato, I. 2023 "<strong></strong>Current Status of Nanomedicine in CNS Cancer Therapeutics in the Post-COVID-19 Era" Preprints. https://doi.org/10.20944/preprints202311.0017.v1
Abstract
Central Nervous System (CNS) cancers pose a formidable challenge in the medical world, characterized by aggressive behaviors and limited therapeutic options. The emergence of nanomedicine has offered new hope in CNS cancer treatment. The COVID-19 pandemic has further accelerated the need for innovative therapeutic strategies, emphasizing the significance of nanomedicine in this era. This mini review explores the current status of nanomedicine in CNS cancer therapy, with a particular focus on the post-COVID-19 landscape. We discuss the unique challenges presented by CNS cancers, the potential of nanomedicine in overcoming these challenges, and the recent developments in the field. Additionally, we highlight the lessons learned from the pandemic and how they can be applied to improve CNS cancer therapeutics. We also shed light on the evolving regulatory landscape and the prospects of personalized nanomedicine in CNS cancer treatment. The integration of nanomedicine in CNS cancer therapy is becoming increasingly promising, and its role in the post-COVID-19 era is poised to shape the future of neuro-oncology.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
